Understanding BTK inhibitor treatment for CLL/SLL in China
Current Status and Influencing Factors of Chinese Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Undergoing Treatment With Bruton's Tyrosine Kinase Inhibitors
The First Affiliated Hospital with Nanjing Medical University · NCT06508684
This study looks at how well BTK inhibitors are working for people with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in China to find the best treatment approaches.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University (other) |
| Locations | 1 site (Nanjin, Jiangsu) |
| Trial ID | NCT06508684 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the current status of BTK inhibitor treatment for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in China. It will involve a multicenter retrospective cross-sectional analysis to gather data on treatment patterns and influencing factors related to BTK inhibitors. By analyzing real-world data, the study seeks to identify optimal treatment strategies for CLL/SLL patients based on their experiences with BTK inhibitors.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 years and older with a confirmed diagnosis of CLL/SLL who have received BTK inhibitor treatment within the specified timeframe.
Not a fit: Patients with other types of lymphoma or those deemed unsuitable for inclusion by the investigators will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights that lead to improved treatment strategies for CLL/SLL patients in China.
How similar studies have performed: While BTK inhibitors are established treatments, this study is significant as it aims to fill a gap in large-scale real-world data regarding their use in China.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years; * Patients with a confirmed diagnosis of CLL/SLL; * Received BTK inhibitor treatment between February 2023 and February 2024. Exclusion Criteria: * Patients with other types of lymphoma; * Cases deemed unsuitable for inclusion in this study by the investigators.
Where this trial is running
Nanjin, Jiangsu
- Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital — Nanjin, Jiangsu, China (RECRUITING)
Study contacts
- Study coordinator: Huayuan Zhu, MD
- Email: huayuan.zhu@hotmail.com
- Phone: 025-58530260
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: CLL/SLL